• 1
    National Cancer Institute. Cancer Stat Fact Sheets. Available at: Accessed February 11, 2008.
  • 2
    American Cancer Society. Cancer Facts & Figures 2007. Available at: Accessed February 11, 2008.
  • 3
    Zheng T,Mayne ST,Boyle P, et al. Epidemiology of non-Hodgkin lymphoma in Connecticut, 1935-1988. Cancer. 1992; 70: 840849.
  • 4
    Groves FD,Linet MS,Travis LB, et al. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000; 92: 12401251.
  • 5
    Morton LM,Wang SS,Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006; 107: 265276.
  • 6
    Gurney KA,Cartwright RA. Increasing incidence and descriptive epidemiology of extranodal non-Hodgkin lymphoma in parts of England and Wales. Hematol J. 2002; 3: 95104.
  • 7
    Abdel-Fattah MM,Yassine OG. Non-Hodgkin's lymphomas in Alexandria, Egypt; incidence rates and trend study (1995-2004). Eur J Cancer Prev. 2007; 16: 479485.
  • 8
    Tirelli U,Errante D,Van GM, et al. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol. 1998; 16: 2734.
  • 9
    Miller TP,Dahlberg S,Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998; 339: 2126.
  • 10
    Fisher RI,Gaynor ER,Dahlberg S, et al. Comparison of a standard regimen (CHOP) with 3 intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993; 328: 10021006.
  • 11
    Lichtman SM,Kolitz J,Budman DR, et al. Treatment of aggressive non-Hodgkin's lymphoma in elderly patients with thiotepa, Novantrone (mitoxantrone), vincristine, prednisone (TNOP). Am J Clin Oncol. 2001; 24: 360362.
  • 12
    Osby E,Hagberg H,Kvaloy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood. 2003; 101: 38403848.
  • 13
    Feugier P,Van Hoof A,Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005; 23: 41174126.
  • 14
    Fisher RI,LeBlanc M,Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005; 23: 84478452.
  • 15
    Liu Q,Fayad L,Cabanillas F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006; 24: 15821589.
  • 16
    Forstpointner R,Dreyling M,Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004; 104: 30643071.
  • 17
    Swenson WT,Wooldridge JE,Lynch CF, et al. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol. 2005; 23: 50195026.
  • 18
    Peters FP,Fickers MM,Erdkamp FL, et al. The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates. Ann Hematol. 2001; 80: 406410.
  • 19
    Coiffier B,Lepage E,Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 235242.
  • 20
    Morrison VA. Non-Hodgkin's lymphoma in the elderly, pt 2: treatment of diffuse aggressive lymphomas. Oncology (Williston Park). 2007; 21: 11911198.
  • 21
    Grann VR,Hershman D,Jacobson JS, et al. Outcomes and diffusion of doxorubicin-based chemotherapy among elderly patients with aggressive non-Hodgkin lymphoma. Cancer. 2006; 107: 15301541.
  • 22
    Cronin DP,Harlan LC,Clegg LX, et al. Patterns of care in a population-based random sample of patients diagnosed with non-Hodgkin's lymphoma. Hematol Oncol. 2005; 23: 7381.
  • 23
    Berrios-Rivera JP,Fang S,Cabanillas ME,Cabanillas F,Lu H,Du XL. Variations in chemotherapy and radiation therapy in a large nationwide and community-based cohort of elderly patients with non-Hodgkin lymphoma. Am J Clin Oncol. 2007; 30: 163171.
  • 24
    Potosky AL,Riley GF,Lubitz JD, et al. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993; 31: 732748.
  • 25
    Warren JL,Klabunde CN,Schrag D,Bach PB,Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40( 8 suppl): IV-318.
  • 26
    Zippin C,Lum D,Hankey BF. Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer. 1995; 76: 23432350.
  • 27
    National Cancer Institute. SEER Data Reporting Tools. Available at: Accessed February 13, 2008.
  • 28
    Du XL,Chan W,Giordano S, et al. Variation in modes of chemotherapy administration for breast carcinoma and association with hospitalization for chemotherapy-related toxicity. Cancer. 2005; 104: 913924.
  • 29
    Du XL,Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol. 2001; 19: 14551461.
  • 30
    Warren JL,Harlan LC,Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002; 40( 8 suppl): IV-5561.
  • 31
    US Public Health Services. International Classification of Diseases. 9th rev, Clinical Modification. 5th ed. Los Angeles, CA: Practice Management Information Corporation; 1996.
  • 32
    Health Care Financing Administration. HCFA Common Procedure Coding System (HCPCS): National Level-II Medicare Codes. Los Angeles, CA: Practice Management Information Corp; 1994.
  • 33
    Du XL,Freeman JL,Goodwin JS. Information on radiation treatment in patients with breast cancer: the advantages of the linked Medicare and SEER data. J Clin Epidemiol. 1999; 52: 463470.
  • 34
    Clarke CA,Glaser SL,Dorfman RF, et al. Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: reliability of diagnosis and subtype classifications. Cancer Epidemiol Biomarkers Prev. 2004; 13: 138143.
  • 35
    Clarke CA,Undurraga DM,Harasty PJ, et al. Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomarkers Prev. 2006; 15: 630638.
  • 36
    Klabunde CN,Potosky AL,Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 12581267.
  • 37
    Charlson ME,Pompei P,Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373383.
  • 38
    Deyo RA,Cherkin DC,Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45: 613619.
  • 39
    Romano PS,Roos LL,Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993; 46: 10751079.
  • 40
    Bach PB,Guadagnoli E,Schrag D, et al. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care. 2002; 40( 8 suppl): IV-1925.
  • 41
    Allison PD. Survival Analysis Using the SAS System: A Practical Guide. Cary, NC: SAS Institute Inc.; 1995.